Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations

Anne Vadin, Corinne Moulon, Valérie Nicolas-Métral, Annick Menétre, Hélène Maby-El Hajami, Stefania Rigotti, Claudia Zanin, Grégoire Vuignaux
Debiopharm International SA, Switzerland

Abstract #547

Debio 1347 is a selective and orally available FGFR1, 2, 3 ATP competitive inhibitor.

Methods

Debio 1347 inhibits tumor growth of a FGFR3-TACC3 translocated bladder cancer model

Results

Table 2. Debio 1347 inhibits tumor growth of a FGFR3-TACC3 translocated bladder cancer model

Table 3: PK/PD relationships between Debio 1347 plasma levels, FGFR23 plasma levels, and tumor growth inhibition in a FGFR translocated bladder cancer model

Table 4: Clinical trial

Conclusions

Debio 1347 is rapidly absorbed after oral administration and plasma exposure increases with dose in a more than a dose-proportional manner. The extent of changes in FGFR plasma levels was correlated with Debio 1347 plasma exposure.

Debio 1347 plasma trough levels below Cmin or Cmax appeared to be correlated with antitumor activity in the BT549 xenograft model, as suggested by the higher efficacy of the 0 mg dose compared to the 10 mg treatment. The magnitude of change in plasma levels above a threshold dose is maintained to achieve optimal antitumor efficacy.

References


Contact

Debiopharm International SA, Geneve, Switzerland

Download

This paper is available in PDF format.